Anna Skakodub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Skakodub has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ankush Bhatia
Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA
17 shared publications - Anne S. Reiner
Memorial Sloan Kettering Cancer Center, New York, New York, USA
17 shared publications - Henry Walch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Ingo K. Mellinghoff
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, USA
17 shared publications - Katherine S. Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Maria Diaz
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York
17 shared publications
Latest Publications
- 1 April 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300470
Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases
PURPOSE: Small cell lung cancer (SCLC) often metastasizes to the brain and has poor prognosis. SCLC subtypes distinguished by expressing transcriptional factors ASCL1 or NEUROD1 have been identified. This study investigates the impact of transcription factor–defined SCLC subtype on incidence and outcomes of brain metastases (BMs). METHODS: Patients with SCLC with ASCL1 (A) and NEUROD1 (N) immunohistochemical expression status were identified and classified: (1) A+/N–, (2) A+/N+, (3) A–/N+, and (4) A–/N–. Cumulative incidence competing risk analyses were used to assess incidence of CNS progression. Cox proportional hazards models were used for multivariable analyses of overall survival (OS) and CNS progression-free survival (CNS-PFS). RESULTS: Of 164 patients, most were either A+/N– or A+/N+ (n = 62, n = 63, respectively). BMs were present at diagnosis in 24 patients (15%). Among them, the 12-month cumulative incidence of subsequent CNS progression was numerically highest for A+/N– (50% [95% CI, 10.5 to 74.7]; P = .47). Among those BM-free at diagnosis, the 12-month cumulative incidence of CNS progression was numerically the highest for A+/N– (16% [95% CI, 7.5 to 27.9]) and A–/N+ (9.1% [95% CI, 0.0 to 34.8]; P = .20). Both subtypes, A+/N– and A–/N+, had worse OS compared with A+/N+ (A+/N–: hazard ratio [HR], 1.62 [95% CI, 1.01 to 2.51]; P < .05; A–/N+: HR, 3.02 [95% CI, 1.35 to 6.76]; P = .007). Excellent response rates (28, 65% CR/PR) across subtypes were seen in patients who had CNS-directed radiotherapy versus systemic therapy alone (9, 36% CR/PR). CONCLUSION: To our knowledge, this report is the first to investigate CNS-specific outcomes based on transcription factor subtypes in patients with SCLC. BM-free patients at diagnosis with A+/N– or A–/N+ subtypes had worse outcomes compared with those with transcriptional factor coexpression. Further investigation into the mechanisms and implications of SCLC subtyping on CNS-specific outcomes is warranted to ultimately guide personalized care.
- 1 April 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300470
Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases
PURPOSE: Small cell lung cancer (SCLC) often metastasizes to the brain and has poor prognosis. SCLC subtypes distinguished by expressing transcriptional factors ASCL1 or NEUROD1 have been identified. This study investigates the impact of transcription factor–defined SCLC subtype on incidence and outcomes of brain metastases (BMs). METHODS: Patients with SCLC with ASCL1 (A) and NEUROD1 (N) immunohistochemical expression status were identified and classified: (1) A+/N–, (2) A+/N+, (3) A–/N+, and (4) A–/N–. Cumulative incidence competing risk analyses were used to assess incidence of CNS progression. Cox proportional hazards models were used for multivariable analyses of overall survival (OS) and CNS progression-free survival (CNS-PFS). RESULTS: Of 164 patients, most were either A+/N– or A+/N+ (n = 62, n = 63, respectively). BMs were present at diagnosis in 24 patients (15%). Among them, the 12-month cumulative incidence of subsequent CNS progression was numerically highest for A+/N– (50% [95% CI, 10.5 to 74.7]; P = .47). Among those BM-free at diagnosis, the 12-month cumulative incidence of CNS progression was numerically the highest for A+/N– (16% [95% CI, 7.5 to 27.9]) and A–/N+ (9.1% [95% CI, 0.0 to 34.8]; P = .20). Both subtypes, A+/N– and A–/N+, had worse OS compared with A+/N+ (A+/N–: hazard ratio [HR], 1.62 [95% CI, 1.01 to 2.51]; P < .05; A–/N+: HR, 3.02 [95% CI, 1.35 to 6.76]; P = .007). Excellent response rates (28, 65% CR/PR) across subtypes were seen in patients who had CNS-directed radiotherapy versus systemic therapy alone (9, 36% CR/PR). CONCLUSION: To our knowledge, this report is the first to investigate CNS-specific outcomes based on transcription factor subtypes in patients with SCLC. BM-free patients at diagnosis with A+/N– or A–/N+ subtypes had worse outcomes compared with those with transcriptional factor coexpression. Further investigation into the mechanisms and implications of SCLC subtyping on CNS-specific outcomes is warranted to ultimately guide personalized care.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period.Experimental Design:We integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics.Results:Using log-linear mixed modeling, the entire cohort (n = 128) had a continuous %TVGR per 6 months of 10.46% [95% confidence interval (CI), 9.11%–11.83%] and a doubling time of 3.5 years (95% CI, 3.10–3.98). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI, 15.57%–22.89%) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI, 7.32%–11.80%; P < 0.0001). Using joint modeling to comodel the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR = 3.83; 95% CI, 2.32–6.30; P < 0.0001).Conclusions:TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period.Experimental Design:We integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics.Results:Using log-linear mixed modeling, the entire cohort (n = 128) had a continuous %TVGR per 6 months of 10.46% [95% confidence interval (CI), 9.11%–11.83%] and a doubling time of 3.5 years (95% CI, 3.10–3.98). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI, 15.57%–22.89%) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI, 7.32%–11.80%; P < 0.0001). Using joint modeling to comodel the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR = 3.83; 95% CI, 2.32–6.30; P < 0.0001).Conclusions:TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S3. Next-Intervention-Free Survival and overall survival.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S3. Next-Intervention-Free Survival and overall survival.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S4. Clinical Characteristics and Tumor Volume Growth During Active Surveillance.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S4. Clinical Characteristics and Tumor Volume Growth During Active Surveillance.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S1. Somatic genomic alterations in the cohort of IDH-mutant gliomas.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S1. Somatic genomic alterations in the cohort of IDH-mutant gliomas.